Pharm

CCR4 Monoclonal Antibody

search

CCR4 Monoclonal Antibody, Mogamulizumab, Mogamulizumab-kpkc, Poteligeo, CCR4 Receptor

  • See Also
  1. Monoclonal Antibody-Mediated Chemotherapy
  2. Targeted Cancer Therapy
  3. Chemotherapy
  4. Monoclonal Antibody
  • Indications
  1. Cutaneous T Cell Lymphoma (Mycosis Fungoides, Sezary Syndrome)
  • Mechanism
  1. CCR4 (Chemokine receptor 4)
    1. CCR4 is a cell surface receptor that binds Cytokines (CCL2, CCL4, CCL5, CCL17 and CCL22)
    2. CCR4 Receptors are most commonly expressed on T-Lymphocytes, Mast Cells, Dendritic Cells and Natural Killer Cells
    3. CCR4 binding by Cytokine triggers chemotaxis of inflammatory cells (e.g. Natural Killer Cells)
  2. CCR4 Monoclonal Antibody (e.g. Mogamulizumab)
    1. Humanized Monoclonal Antibody selectively binds CCR4 and blocks chemotaxis, T-Cell proliferation and Angiogenesis
  • Medications
  1. Mogamulizumab-kpkc (Poteligeo) solution for injection
  • Dosing
  1. See other references for disease specific dosing protocols
  • Adverse Effects
  1. Infusion Reaction
  2. Dermatitis
    1. Hold for moderate to severe dermatitis
  3. Graft Versus Host Disease
    1. Status-post transplant patients
  4. Other common adverse effects
    1. Diarrhea
    2. Myalgias
  • Safety
  1. Avoid in Lactation
  2. Avoid in pregnancy (all trimesters, unknown safety)
    1. Use reliable Contraception
  • Resources
  1. Mogamulizumab (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e53960ab-42a1-40d1-9c7d-eb013fe7f18f
  • References
  1. Fernández-Guarino (2024) Int J Mol Sci 25(4):2203 +PMID: 38396877 [PubMed]